What You Should Know:
– Salesforce (NYSE: CRM), the world’s #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement…
Continue Reading
Dr. Jason Acker, MBA, PhD, Co-founder of PanTHERA CryoSolutions
Cell and gene therapies (CGTs) are reshaping medicine. Hundreds of clinical trials are underway worldwide, and the first wave of commercial therapies is already changing the…
Continue Reading
Exclusive: Pangaea Data, AstraZeneca leverage AI to detect rare diseases | MobiHealthNews
Skip to main content…
Continue Reading
Rare diseases (RD) affect 3.5–5.9% of the global population, yet patients often endure a diagnostic odyssey averaging around 5–6 years, navigating multiple specialties and referrals. This study investigates the use of information content (IC)…
Continue Reading
Rare diseases affect over 300 million people worldwide and pose unique research challenges. In silico approaches, such as mechanistic models, machine learning, and simulations, offer scalable tools for disease characterisation, drug discovery, and virtual…
Continue Reading
Series A Investment Will Advance the Company’s Efforts to Give Patients the Power to Drive Research on Rare Diseases and Chronic Conditions
Folia Health, the patient-driven health company and pioneer of home-reported outcomes (HROs), committed…
Understanding the Burden of Rare Diseases
Rare diseases represent a significant challenge for both patients and healthcare systems worldwide. Research demonstrates that the collective burden of rare diseases is comparable to that of major conditions…
What You Should Know:
– San Francisco-based Citizen Health, a platform empowering patients with rare and complex conditions, secures $30M in Series A funding led by 8VC, with participation from Transformation Capital and Headline, bringing…
Continue Reading
Early detection of eye diseases is vital for preventing vision loss. Existing ophthalmic artificial intelligence models focus on single modalities, overlooking multi-view information and struggling with rare diseases due to long-tail distributions. We propose…
Continue Reading
There are over 7000 rare diseases, some affecting 3500 or fewer patients in the United States. Due to clinicians’ limited experience with such diseases and the heterogeneity of clinical presentations, ~70% of individuals seeking…
Continue Reading
